×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EXEL – exelixis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EXEL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
04:05 pm
exel
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
Low
Report
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
11/18
09:00 am
exel
Exelixis (NASDAQ:EXEL) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/10
01:43 pm
exel
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
Low
Report
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
11/7
02:55 pm
exel
Company News for Nov 6, 2025 [Yahoo! Finance]
Low
Report
Company News for Nov 6, 2025 [Yahoo! Finance]
11/6
09:40 pm
exel
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still [Seeking Alpha]
Low
Report
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still [Seeking Alpha]
11/6
04:05 pm
exel
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Low
Report
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
11/6
12:48 pm
exel
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at UBS Group AG from $35.00 to $40.00. They now have a "neutral" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at UBS Group AG from $35.00 to $40.00. They now have a "neutral" rating on the stock.
11/5
02:21 pm
exel
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at TD Cowen from $44.00 to $51.00. They now have a "buy" rating on the stock.
Low
Report
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at TD Cowen from $44.00 to $51.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/26
04:05 pm
exel
Form 4 EXELIXIS, INC. For: Nov 25 Filed by: Caligan Partners LP
Low
Report
Form 4 EXELIXIS, INC. For: Nov 25 Filed by: Caligan Partners LP
11/24
07:48 pm
exel
Form 4 EXELIXIS, INC. For: Nov 20 Filed by: Haley Patrick J.
Low
Report
Form 4 EXELIXIS, INC. For: Nov 20 Filed by: Haley Patrick J.
11/24
07:48 pm
exel
Form 4 EXELIXIS, INC. For: Nov 21 Filed by: Aftab Dana
Low
Report
Form 4 EXELIXIS, INC. For: Nov 21 Filed by: Aftab Dana
11/20
07:52 pm
exel
Form 3 EXELIXIS, INC. For: Nov 07 Filed by: Hefti Brenda
Low
Report
Form 3 EXELIXIS, INC. For: Nov 07 Filed by: Hefti Brenda
11/20
04:02 pm
exel
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
Low
Report
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
11/19
08:11 pm
exel
Form 4 EXELIXIS, INC. For: Nov 17 Filed by: Oliver Bob
Low
Report
Form 4 EXELIXIS, INC. For: Nov 17 Filed by: Oliver Bob
11/13
07:13 pm
exel
Form 4 EXELIXIS, INC. For: Nov 12 Filed by: PAPADOPOULOS STELIOS
Low
Report
Form 4 EXELIXIS, INC. For: Nov 12 Filed by: PAPADOPOULOS STELIOS
11/13
07:13 pm
exel
Form 4 EXELIXIS, INC. For: Nov 11 Filed by: Aftab Dana
Low
Report
Form 4 EXELIXIS, INC. For: Nov 11 Filed by: Aftab Dana
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/17
Form 4 EXELIXIS, INC. For: Apr 15 Filed by: SCANGOS GEORGE A
21.5%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
6/20 Exelixis lower after IMspire170 fails to meet primary endpoint [Seeking Alpha] 9.0%
4/22 Form 4 EXELIXIS, INC. For: Apr 20 Filed by: Haley Patrick J. 7.6%
4/3 Form 4 EXELIXIS, INC. For: Apr 03 Filed by: WYSZOMIERSKI JACK L 6.7%
1/13 Form 8-K EXELIXIS, INC. For: Jan 12 6.6%
1/7 Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 6.1%
7/15 Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors 6.0%
11/13 Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 6.0%
4/21 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Barclays PLC. They now have a $30.00 price target on the stock. 5.6%
1/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $21.00 price target on the stock, down previously from $22.00. 4.9%
TOP News Decliners
10/30
Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update
-14.9%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
3/13 Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at William Blair. -13.8%
1/24 Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha] -8.7%
7/31 Form 8-K EXELIXIS, INC. For: Jul 31 -6.5%
10/3 Form 4 EXELIXIS, INC. For: Oct 01 Filed by: Schwab Gisela -6.3%
4/9 Form DEF 14A EXELIXIS, INC. For: May 20 -5.2%
4/29 Form 4 EXELIXIS, INC. For: Apr 27 Filed by: MORRISSEY MICHAEL -5.0%
12/5 How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay? [Yahoo! Finance News] -4.6%
3/10 Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript) [Seeking Alpha] -4.6%
12/6 Hedge Funds Are Warming Up To Exelixis, Inc. (EXEL) [Yahoo! Finance News] -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: